文献速递神经MRDSA

烟雾病高分辨率MRI血管壁强化:危险因素与临床结局

High-resolution MRI vessel wall enhancement in moyamoya disease: risk factors and clinical outcomes.
PubMed 文献 · Eur Radiol · 2024-01-04

本研究纳入283例烟雾病患者,用高分辨率MRI评估血管壁强化(VWE),84例存在VWE;VWE组入院时改良Rankin量表评分更高(p=0.014),缺血和出血发生率更高(p=0.002)。VWE的危险因素包括RNF213 p.R4810K变异(OR 2.01,95%CI 1.08-3.76,p=0.028)、高同型半胱氨酸血症(OR 5.08,95%CI 2.34-11.05,p<0.001)和吸烟史(OR 3.49,95%CI 1.08-11.31,p=0.037);随访63.9±13.2个月(中位65个月)期间发生18例复发性卒中事件,Cox回归显示VWE和RNF213 p.R4810K变异是卒中的危险因素。

要点

  • 烟雾病患者基线存在血管壁强化与不良预后显著相关。
  • RNF213 p.R4810K变异与血管壁强化及不良预后强相关。
  • 高同型半胱氨酸血症和吸烟是血管壁强化的独立危险因素。

核心结论

  • RNF213 p.R4810K变异与烟雾病血管壁强化及不良预后强相关,高同型半胱氨酸血症和吸烟是血管壁强化的独立危险因素。

研究设计与样本

  • 研究纳入283例烟雾病患者,采用高分辨率磁共振成像和传统血管造影检查,根据高分辨率磁共振成像分为血管壁强化组(84例)和无血管壁强化组。

关键影像表现/征象

  • 血管壁强化组入院时改良Rankin量表评分高于无血管壁强化组(p=0.014)。
  • 血管壁强化组缺血和出血发生率高于无血管壁强化组(p=0.002)。

诊断标准与关键数值

  • RNF213 p.R4810K变异与血管壁强化的OR为2.01(95%CI 1.08-3.76,p=0.028)。
  • 高同型半胱氨酸血症与血管壁强化的OR为5.08(95%CI 2.34-11.05,p<0.001)。
  • 吸烟史与血管壁强化的OR为3.49(95%CI 1.08-11.31,p=0.037)。

临床应用与阅片要点

  • 高分辨率磁共振成像显示的血管壁强化可用于烟雾病风险分层,结合RNF213 p.R4810K变异、高同型半胱氨酸血症和吸烟史评估不良预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Intracranial vessel wall enhancement (VWE) on high-resolution magnetic resonance imaging (HRMRI) is associated with the progression and poor prognosis of moyamoya disease (MMD). This study assessed potential risk factors for VWE in MMD.

METHODS: We evaluated MMD patients using HRMRI and traditional angiography examinations. The participants were divided into VWE and non-VWE groups based on HRMRI. Logistic regression was performed to compare the risk factors for VWE in MMD. The incidence of cerebrovascular events of the different subgroups according to risk factors was compared using Kaplan-Meier survival and Cox regression.

RESULTS: We included 283 MMD patients, 84 of whom had VWE on HRMRI. The VWE group had higher modified Rankin Scale scores at admission (p = 0.014) and a higher incidence of ischaemia and haemorrhage (p = 0.002) than did the non-VWE group. Risk factors for VWE included the ring finger protein 213 (RNF213) p.R4810K variant (odds ratio [OR] 2.01, 95% confidence interval [CI] 1.08-3.76, p = 0.028), hyperhomocysteinaemia (HHcy) (OR 5.08, 95% CI 2.34-11.05, p < 0.001), and smoking history (OR 3.49, 95% CI 1.08-11.31, p = 0.037). During the follow-up of 63.9 ± 13.2 months (median 65 months), 18 recurrent stroke events occurred. Cox regression showed that VWE and the RNF213 p.R4810K variant were risk factors for stroke.

CONCLUSION: The RNF213 p.R4810K variant is strongly associated with VWE and poor prognosis in MMD. HHcy and smoking are independent risk factors for VWE.

CLINICAL RELEVANCE STATEMENT: Vessel wall enhancement in moyamoya disease is closely associated with poor prognosis, especially related to the ring finger protein 213 p.R4810K variant, hyperhomocysteinaemia, and smoking, providing crucial risk assessment information for the clinic.

KEY POINTS: • The baseline presence of vessel wall enhancement is significantly associated with poor prognosis in moyamoya disease. • The ring finger protein 213 p.R4810K variant is strongly associated with vessel wall enhancement and poor prognosis in moyamoya disease. • Hyperhomocysteinaemia and smoking are independent risk factors for vessel wall enhancement in moyamoya disease.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Hao F, Han C, Lu M, et al. High-resolution MRI vessel wall enhancement in moyamoya disease: risk factors and clinical outcomes. Eur Radiol. 2024. PMID: 38172442. doi:10.1007/s00330-023-10535-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。